Company intelligence

IRWD

Ironwood Pharmaceuticals, Inc. · NASDAQ · Healthcare

Price$4.29-2.28% · −$0.10

Market cap706.19MEquity value

P / E5.5Trailing ratio

Volume1.03MLatest session

Market data

IRWD price chart

TradingView

Related signals

1 min delayed

Browse public IRWD signals with their source context and measured market impact. Open any signal for its permanent analysis page.

IRWDApr 14, 2025+12.14% since signal

Ironwood Pharmaceuticals Stock Plunges, FDA Wants Another Trial For Gastrointestinal Drug

FDA requires confirmatory Phase 3 trial for apraglutide approval. Ironwood engaged Goldman Sachs to explore strategic alternatives. Strong efficacy data from STARS trial but lower than expected doses. Completion of NDA submission expected by Q3 2025. IRWD stock dropped 30.28% to 66 cents.

View signal analysis

IRWDMay 10, 2024+0.36% since signal

Ironwood (IRWD) Q1 Earnings & Revenues Fall Shy of Estimates

- IRWD reported an adjusted loss of 2 cents per share for Q1 2024. - Total revenues in Q1 were $74.9 million, missing estimates due to Linzess sales. - IRWD revised its 2024 revenue guidance downwards, causing a 17% stock decline. - IRWD is evaluating apraglutide in various studies for potential development and submission. - Shares of IRWD have plunged 41.1% year to date. Price Impact Rating: Bearish Impact Horizon Rating: Short-term Type: Earnings

View signal analysis

Research